OIS@AAO - October 16, 2014

2014 CHICAGO, IL

SUMMIT WORKBOOK

WORKBOOK

OCTOBER, 16

W W W. O I S . N E T

2014 SPONSORS EXCLUSIVE

PREMIER

MAJOR

STRATEGIC

SUPPORTING

PAN

FOUNDING

PTICA

3

Welcome to the 6th Annual

Ophthalmology Innovation Summit @ AAO!

The mission of OIS is to support and drive innovation by facilitating meaningful interactions and business partnerships between CEOs of private companies, investors, industry executives, physicians and academic scientists in the ophthalmic space.

Thirty-three emerging drug, device and digital ophthalmology companies were selected to present in the morning. The program will then feature a plenary talk at lunch from the recently appointed head of Alcon, Jeff George, followed by the 2014 OIS Innovator Award Presentation. The rest of the afternoon will include timely and topical panel discussions around the FDA, funding trends, going public and industry consolidation. We hope you enjoy the rapid-fire presentations, interactive panels and most importantly the networking.

On behalf of the OIS Advisory Board, sponsors and producers, we are pleased to have your participation in what is now a bi-annual industry tradition. Stay on the lookout for future OIS podcasts and other new media content to keep you up to date on what’s trending in ophthalmology innovation.

Sincerely,

OIS CHAIRMAN

OIS CO-CHAIRMAN

OIS CO-CHAIRMAN

Emmett T. Cunningham Jr. MD, PhD, MPH Partner Clarus Ventures

Gilbert H. Kliman, MD Managing Director InterWest Partners

William J. Link, PhD Managing Director Versant Ventures

GENERAL INFORMATION

4 ABOUT OIS

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues, both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

SUMMIT PROGRAM

General Session programming will take place in the Grand/State Ballroom on the fourth floor of the Palmer House Hilton.

HELP DESK

Have a question or need help with anything during OIS? Stop by the Help Desk to get the answers you need. The Help Desk is located outside of the Grand/State Ballroom in the West Lounge pre-function space and is available to you from 6:30am to 5:30pm.

FOOD FUNCTIONS

The luncheon will take place outside of the Grand/State Ballroom in the West Lounge pre-function space.

Breakfast, Cocktail Reception and all Networking Breaks will take place on the fourth floor in the Upper Exhibit Hall, just a few steps down from the West Lounge pre-function space.

NETWORKING LOUNGE

The Networking Lounge is located on fourth floor in the Upper Exhibit Hall, just a few steps down from the Ballroom Foyer. There is space for scheduled for sporadic meetings. Schedule a meeting with fellow attendees through the OIS mobile APP.

WIFI

For your convenience, OIS@AAO is providing complimentary wireless access in the meeting area.

SSID/Name: HILTON WEB Password: ALPHAEON (Case Sensitive)

SOCIAL MEDIA Twitter: @OISTWEETS #OISAAO Linkedin: Ophthalmology Innovation Summit Google+: Ophthalmologysummit

Sponsored By:

5

To enhance your networking experience, there is a mobile APP for summit attendees. The OIS@AAO app provides the perfect opportunity for you to easily connect with other attendees and speakers.

Some highlights of the APP include: 1.

2.

3.

4.

5.

6.

7.

8.

9.

GENERAL INFORMATION

OIS@AAO MOBILE APP

Attendees - view profiles for all attendees, participants and sponsors Messages - send and receive private messages with other attendees Meetings - schedule on-site meetings with attendees throughout the day Agenda - view an overview of the programming in the agenda at-a-glance or explore topics and speakers in the detailed agenda Speaker Bios - read background details on all participants Sponsor Profiles - view company overviews for all sponsors Slide Deck Viewing - all PowerPoint presentations are available for view under the “Presentations” tab Surveys - help us to continue to improve the summit and share your feedback. There are surveys to rate each session located within the detailed agenda.

We have an exciting new feature in the app exclusively for physicians which gives you access to the “ShoutMD” social networking platform, compliments of ALPHAEON. Be sure to check it out and create an account. There will also be Alphaeon staff available in the exhibit hall to help you sign up.

DOWNLOAD THE OIS MOBILE APP To download the OIS Mobile APP, visit the APP Store or GooglePlay and search for “OIS”. Please refer to the email entitled “Welcome to The Ophthalmology Innovation Summit @AAO” for your login details.

IPHONE

IPAD

ANDROID

INDUSTRY SURVEY In the OIS@AAO Mobile APP there is a tab titled “Industry Survey.” OIS is looking for feedback from the community to keep up-to-date on what is trending in ophthalmology.

MOBILE PHONES Please make sure to put your mobile devices on silent or vibrate mode during sessions. Do not answer your phone in the meeting room, please go outside to take any calls.

LOST AND FOUND Please bring any articles found to the OIS@AAO Help Desk located outside of the Grand/State Ballroom.

SUMMIT CONTENT/PRESENTATIONS All PowerPoint presentations are available in the OIS Mobile APP. Post-summit video presentations will be available at www.ois.net.

AGENDA

6 6:30 - 7:30 AM REGISTRATION CHECK-IN & BREAKFAST

Hosted By:

7:30 - 7:45 AM WELCOME & CHAIRMAN’S OPENING REMARKS 2014 - Year In Review The past year in ophthalmology has been filled with financings, scientific breakthroughs, FDA approvals, M&A deals and IPOs. OIS Founding Chairman, Emmett Cunningham Jr., MD, will walk attendees through the significant points throughout the year.

Emmett T. Cunningham Jr. MD, PhD, MPH Partner - Clarus Ventures See bio on page 32

7:45 - 9:37 AM BIOPHARMA COMPANY SHOWCASE

CO-MODERATORS

Robert Dempsey Vice President & Business Unit Head Shire Ophthalmics See bio on page 32

Calvin W. Roberts, MD Executive Vice President & CMO Bausch + Lomb See bio on page 52

7:45 - 7:53 AM ALLYSTA PHARMACEUTICALS Allysta Pharmaceuticals, based in the San Francisco Bay Area, is engaged in developing innovative new treatments for serious eye diseases. Allysta is developing Aly1337, a novel small molecule multikinase inhibitor discovered by D. Western Therapeutics Institute (Nagoya, Japan) targeting the trabecular meshwork for treatment of glaucoma.

Henry Hsu, MD Founder & CEO See bio on page 40

7:53 - 8:01 AM AERIE PHARMACEUTICALS Aerie is a clinical-stage pharmaceutical company with a focus on glaucoma therapies. Aerie commenced two Phase 3 registration trials in the US for triple-action Rhopressa™ named “Rocket 1” and “Rocket 2, a third Phase 3 safety trial, named “Rocket 3,” in Canada and a Phase 2b clinical trial for quadruple-action Roclatan™.

Vicente Anido Jr., PhD CEO See bio on page 26

7

ONL Therapeutics preserves vision through the protection of photoreceptors from retinal disease. ONL is developing ONL-101, a small injectable peptide that blocks photoreceptor apoptosis. Initial development targets retinal detachment with a neoadjuvant therapy at time of diagnosis and prior to surgery.

Further development will protect photoreceptors until the disease is stabilized.

John Freshley CEO See bio on page 36

8:09 - 8:17 AM KALA PHARMACEUTICALS Kala Pharmaceuticals, Inc. is advancing innovative nanotechnology-based treatments for ocular diseases with significant unmet needs in both front and back of the eye. Kala leverages the company’s proprietary Mucus Penetrating Particle platform technology to develop topical ophthalmic formulations that enhance ocular tissue exposure by facilitating penetration through the mucus layer.

Charlie McDermott Interim President & CBO See bio on page 44

8:17 - 8:25 AM MC2 BIOTEK GROUP The privately held MC2 Biotek is using its unique and patented oil-in-water dispersion - PAD™ Technology - in the ophthalmic and dermatological fields. PAD™ Technology enables release of the full potential of API’s and is the basis for comfortable and patented topical drugs that will improve patient compliance and clinical benefits.

Jesper J. Lange President & Co-Founder See bio on page 42

8:25 - 8:33 AM NOVALIQ GMBH Novaliq GmbH, based in Heidelberg, is a drug delivery company that is developing a superior generation of innovative ocular formulations for poorly soluble drugs. The patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be easily applied in the form of topical eye drops.

Bernhard Günther CEO See bio on page 38

AGENDA

8:01 - 8:09 AM ONL THERAPEUTICS

9

Mobius Therapeutics™ believes that retasking of molecules is more efficient than drug discovery.

Standard of care indications creates NDA’s with less burdensome provisions. The resulting entity creates 6 products in multiple subspecialties. Revenues fund new solutions to existing problems for evolving products and procedures.

Ed Timm President & CEO See bio on page 54

8:41 - 8:49 AM GRAYBUG GrayBug has developed a technology to reduce the frequency of treatment injections to every 4 to 6 months, reducing risks associated with repeated intraocular injections. In addition, GrayBug is applying its novel technology to a lead compound that blocks both key pathways of neovascularization in w-AMD, VEGF and PDGF. Michael O’Rourke President & CEO See bio on page 48

8:49 - 8:57 AM AVALANCHE BIOTECHNOLOGIES Avalanche, a clinical-stage biotechnology company, discovers and develops novel gene therapies to treat sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, Avalanche provides long-term benefits or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.

Thomas W. Chalberg, PhD Founder & CEO See bio on page 30

8:57 - 9:05 AM ALLEGRO OPHTHALMICS Allegro quickly, safely and cost-effectively bring to market new and improved treatment options for the leading causes of blindness. In only four years, Allegro has progressed Luminate® from drug discovery, to establishing safety and initial efficacy in both animals and human patients, to phase 2 clinical trials in DME and vitreomacular traction.

Vicken Karageozian, MD Co-Founder & CTO See bio on page 40

AGENDA

8:33 - 8:41 AM MOBIUS THERAPEUTICS

AGENDA

10 9:05 - 9:13 AM TRANSLATUM MEDICUS Translatum Medicus inc (TMi) de-risks and accelerates drug development for dry Age Related Macular Degeneration. TMi’s technologies include a pre-clinical model that mimics advanced dry AMD and aligns with clinical trial endpoints, and TMi018, that dose-dependently protects against RPE loss. TMi-018 is safe in clinical studies for non-ophthalmic indications.

Shelley Boyd, MD, FRCSC President & CSO See bio on page 28

9:13 - 9:21 AM OPHTHOTECH Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration. Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs.

David R. Guyer, MD CEO See bio on page 38

9:21 - 9:29 AM PANOPTES Panoptes is a privately-held biotech company focused on developing small molecule based therapies to treat severe eye diseases. The Panoptes team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development for uveitis, followed by dry eye disease and viral conjunctivitis.

Franz Obermayr, PhD Co-Founder & CEO See bio on page 48

9:29 - 9:37 AM XOMA CORPORATION XOMA’s innovative products candidates are a result of its focus on allosteric modulation, offering opportunities to develop new classes of therapeutic antibodies. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis, and ongoing studies in other IL-1-mediated diseases.

Paul Rubin, MD CMO See bio on page 52

PROUD TO BE A PREMIER SPONSOR OF

The Ophthalmology Innovation Summit at AAO

AGENDA

12 9:37 - 10:07 AM NETWORKING BREAK 10:07 - 11:51 AM DEVICE, DELIVERY & DIAGNOSTICS COMPANY SHOWCASE

CO-MODERATORS

Laurent Attias Head, Global Commercial Strategy Alcon See bio on page 26

Jane Rady Divisional Vice President Business Development Abbott Medical Optics See bio on page 50

10:07 - 10:15 AM TEARSCIENCE TearScience® has pioneered ophthalmic procedures and devices that identify, diagnose and treat evaporative dry eye. The TearScience® in-office Dry Eye Solution includes the SPEED© Dry Eye Questionnaire, Korb MGE™, LipiView® Ocular Surface Interferometer and LipiFlow® treatment device along with a simplified implementation plan, practice marketing tools, and proven procedure support.

Tim Willis Co-Founder & CEO See bio on page 54

10:15 - 10:23 AM WAVETEC VISION SYSTEMS WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. Our revolutionary ORA System® provides intraoperative refractive information to ophthalmologists worldwide, allowing them to deliver the best possible vision for their cataract patients.

Thomas G. Frinzi President & CEO See bio on page 36

10:23 - 10:31 AM POWERVISION PowerVision, Inc. has developed a proprietary fluid-controlled accommodating intraocular lens (IOL) technology designed to restore youthful vision to millions of middle aged or elderly individuals. The Company has proven in recent clinical trials that it can deliver clear near, intermediate and distance vision with its fully injectable accommodating device.

Barry Cheskin President & CEO See bio on page 32

13

Avedro is a privately held medical device and pharmaceutical company developing corneal cross-linking, a non-invasive treatment for refractive disorders and certain pathologies. Avedro sells in 62 countries and recently submitted an NDA to the FDA. Avedro is also developing, Photorefractive Intrastromal Cross-Linking (PiXL™), for post-cataract ametropia and refractive correction.

David Muller, PhD President & CEO See bio on page 46

10:39 - 10:47 AM IMPLANDATA OPHTHALMIC PRODUCTS GMBH

Implandata Ophthalmic Products GmbH

Implandata Ophthalmic Products, an ophthalmic device and digital health company, offers a solution for improved glaucoma care. Implandata‘s implantable intraocular pressure sensors, it is possible to measure circadian intraocular pressure (IOP) variations and IOP at home. Digital health integration will increase quality of care dramatically,resulting in improved therapy and better disease outcome.

Max G. Ostermeier, MBA Co-Founder & General Manager See bio on page 48

10:47 - 10:55 AM INNFOCUS InnFocus MicroShunt ™ addresses the largest glaucoma patient segment and has achieved mean post op IOP’s below 14 mm Hg, and 80% med reduction. IOP reduction at 3 months similar to 3 year.

By 12/31/14, over 20 doctors will have treated over 150 patients, followed for up to 3 years.

Russell Trenary President & CEO See bio on page 54

10:55 - 11:03 AM IOPTIMA IOPtima Ltd., a Bio-Light company (BOLT:TASE) is a developer of laser-assisted surgical ophthalmic devices. The company’s flagship product, the IOPtimate™, is a surgical system to treat Glaucoma, utilizing a CO2 laser technology to significantly reduce internal eye pressure (“IOP”), by restoring the natural fluid percolation without penetrating into the eye.

Ronen Castro CEO See bio on page 30

AGENDA

10:31 - 10:39 AM AVEDRO

AGENDA

14 11:03 - 11:11 AM I-OPTICS i-Optics pioneers smart and superior eye diagnosis solutions that are affordable, fast and user-friendly for care providers worldwide. Their innovations include: Cassini – A first-of-its-kind Corneal Shape Analyzer, EasyScan – A breakthrough, zero-dilation retinal imaging system to diagnose retinal diseases, and EyePrevent –An effective and cost-efficient retinal disease screening service.

Jeroen Cammeraat CEO See bio on page 30

11:11 - 11:19 AM NEUROTECH Neurotech Pharmaceutical’s core technology, Encapsulated Cell Therapy (ECT), is a proprietary firstin-class drug delivery platform for the treatment of chronic eye diseases. The ECT implant enables continuous immune-privileged production and delivery of therapeutic proteins, derived from a customized cell line, for at least two years to the posterior segment.

Quinton Oswald President & CEO See bio on page 50

11:19 - 11:27 AM FORSIGHT VISION5

ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy.

John Maroney CEO See bio on page 44

11:27 - 11:35 AM MATI THERAPEUTICS Mati is developing a sustained drug delivery platform to treat various ocular diseases including glaucoma using punctal plugs as an anchoring device to deliver drugs to the tear film of the eye. The lead product is completing Phase II trials using latanoprost with plans to start Phase III in 2015.

Robert Butchofsky Founder & CEO See bio on page 30

15

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The Company is currently evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved.

Amarpreet Sawhney, PhD President & CEO See bio on page 52

11:43 - 11:51 AM ALIMERA SCIENCES Alimera Sciences is a pharmaceutical company focused on diseases affecting the retina. Its product, ILUVIEN® (fluocinolone acetonide intravitreal implant) has received marketing authorization for chronic diabetic macular edema considered insufficiently responsive to available therapies in Austria, Denmark, France, Italy, Norway, Portugal and Spain, and has been launched in Germany and the UK.

Dan Myers President & CEO See bio on page 46

11:51 - 12:21 PM DIGITAL OPHTHALMOLOGY SHOWCASE

MODERATED BY:

Gilbert H. Kliman, MD Managing Director InterWest Partners See bio on page 42

11:51 - 11:56 AM CHECKEDUP CheckedUp empowers patients to take a more active role in their health. Through the app, patients can learn about treatment options, prepare for procedures, request more information from their doctor and receive medication and appointment reminders, as well as coupons and vouchers from the convenience of their computer, tablet or phone.

Richard M. Awdeh, MD Founder & CEO See bio on page 28

AGENDA

11:35 - 11:43 AM OCULAR THERAPEUTIX

The world’s leading ophthalmic product development firm

30 1300 37

years of experience development projects new product approvals around the world

It all adds up to Ora stands ready with over 100 ophthalmic professionals, three decades of regulatory experience, the world’s largest network of ophthalmic clinical sites, early stage development captial to help you turn your most promising ideas into profitable products.

300 Brickstone Square | Andover, MA 01810 | (978) 494-4899 300 Brickstone Square | Andover, MA 01810 | (978) 494-4899 www.oraclinical.com/ascrs ois.oraclinical.com

17

Gobiquity mobile health brings specialty testing into primary care using mobile technology to capture clinically significant data. GoCheck Kids is the first product to be commercialized in their pipeline of digital diagnostics and screens young kids for risks of amblyopia, the preventable leading cause of vision loss in children.

Michael Brownell CEO See bio on page 28

12:01 - 12:06 PM DIGISIGHT

DigiSight

TM

DigiSight Technologies, Inc. bridges the information gap between providers and mobile diagnostics. The company’s initial focus is to become a connectivity platform for ophthalmology. Ophthalmology is a specialty rapidly moving in-office diagnostics to mobile platforms. DigiSight Technologies facilitates this movement and enables the medical home concept to become reality.

Doug Foster CEO See bio on page 36

12:06 - 12:11 PM VESTRUM HEALTH The mission of Vestrum Health is to capture the value of EHR data for the benefit of physicians, their patients and the healthcare industry. Vestrum Health aggregates EHR data from demographically and geographically diverse physician panels into specialty-specific databases and products that have commercial value to healthcare and financial industries.

Tom Brogan Chairman of the Board See bio on page 28

12:11 - 12:16 PM APPVISIT Improve patient care, save time and increase revenue. AppVisit facilitates e-visits between you and your patients. Offer asynchronous (no appointment necessary) virtual visits to your patients on smartphones, tablets, and PC’s. AppVisit works for almost any patient condition and is also great for pre-visit intake forms, copayment collection, chronic condition management and post-visit instructions.

Harvey Fishman, MD, PhD Co-Founder & Medical Director See bio on page 34

AGENDA

11:56 - 12:01 PM GOBIQUITY

AGENDA

18 12:16 - 12:21 PM ASSORT ASSORT ® is an ophthalmic software manufacturer based in Melbourne, Australia and founded by ophthalmologist Dr Noel Alpins in 1992. The ASSORT® suite of products, which are designed for use in planning and analysing cataract and refractive surgery, have extensive international patent and trademark protection.

Noel Alpins, MD, FACS CEO See bio on page 26

12:21 - 12:41 PM DIGITAL OPHTHALMOLOGY The Alcon/Google Partnership & Beyond The Google/Alcon partnership is one of the more intriguing deals in ophthalmology in recent years. Hear the details of how this joint-effort developed the next generation of contact lenses directly from those involved.

PANELISTS:

Laurent Attias Head, Global Commercial Strategy Alcon See bio on page 26

MODERATED BY:

Brian P. Otis, PhD Founder, Smart Contact Lens Project Google X See bio on page 48

12:41 PM LUNCHEON COMMENCES

Gilbert H. Kliman, MD Managing Director InterWest Partners See bio on page 42

Hosted By:

1:10 - 1:35 PM PLENARY KEYNOTE Accelerating Innovation in Ophthalmology For over 70 years, Alcon has built its leadership position in eye care through continuous innovation. Leveraging a strong innovation pipeline, coupled with acquisitions and licensing deals, Alcon is capitalizing on new technologies that will further expand one of the healthcare industry’s fastest-growing sectors.

Jeff George President & Global Head Alcon See bio on page 38

Advanced Corneal Cross-Linking: Topography Guided Refractive CXL An Evening Event at AAO Join Avedro for an evening event at AAO featuring global thought leaders speaking on advanced topics in corneal cross-linking.

Saturday, October 18th 6:00 pm - 8:00 pm Hyatt Regency Chicago Grand CD North 151 E. Wacker Drive Chicago, IL 60601

~cocktail reception to begin at 6:00 pm~

Visit www.avedro.com/AAO2014 to register, or scan QR Code now

Visit Booth #2175 for device demos!

AAO | October 18-21 | Chicago

781.768.3400 | info@avedro.com | www.avedro.com Avedro’s cross-linking systems and family of riboflavin products are not for sale in the US. MA-00396A

AGENDA

20 1:35 - 2:00 PM OIS INNOVATOR AWARD PRESENTATION OIS continues to recognize trailblazers who have made exceptional contributions to ophthalmic innovation and entrepreneurship. Since the first award was presented in 2009, OIS has honored nine individuals who have achieved outstanding success in advancing ophthalmic innovation. The 2014 OIS Innovator Awards goes to AGTC.

Susan Washer President & CEO See bio on page 54

William W. Hauswirth, PhD Co-Founder See bio on page 38

Nicholas Muzyczka, PhD Co-Founder See bio on page 46

2:00 PM LUNCHEON CONCLUDES 2:00 - 2:07 PM OPHTHALMIC INNOVATION 2014 “A View From The AAO” The aging global population continues to amp up demand for devices and drugs capable of treating the more vexing ophthalmic conditions. As a kickoff to its annual meeting, the CEO of the nation’s premier ophthalmology group will detail how industry is rising to supply physicians and patients with the necessary tools.

David W. Parke, MD CEO American Academy of Ophthalmology See bio on page 50

2:07 - 2:15 PM OPHTHALMIC INNOVATION 2014 “A View From The NEI” The surest supply of new drugs and devices will come through research funded with both public and private dollars. Hear how the NEI at the NIH will continue to nurse and nurture some of ophthalmology’s most innovative ideas.

Matthew J. McMahon, PhD Director, Office of Translational Research National Eye Institute National Institutes of Health See bio on page 46

AcuFocus, Inc.

Expanding Vision Innovations Visit us at AAO Suite #4648 acufocus.com MKU-102 Rev B

RETINAL DISEASE IS OUR FOCUS Visit us at the AAO Booth 2834

To learn more, visit www.alimerasciences.com

AGENDA

22 2:15 - 2:20 PM HOUSTON, WE HAVE A PROBLEM Visual Disorders In Space And How Ophthalmology Can Help Dr. Dorit Donoviel, PhD, Deputy Chief Scientist & Industry Forum Lead of the National Space Biomedical research Institute, will announce the creation of a new partnership between her agency and the ophthalmic industry, which plans to find ways to prevent and treat many of the (remove) eye issues associated with space travel.

Dorit B. Donoviel, PhD Deputy Chief Scientist & Industry Forum Lead National Space Biomedical Research Institute See bio on page 34

2:20 - 2:50 PM FDA Q&A Industry’s hot and cold relationship with the FDA appears to be undergoing a warming trend as executives and entrepreneurs speak of the agency as a partner, rather than an adversary. In this discussion, senior FDA officials will share how ophthalmology companies can continue working well with the regulatory body.

PANELISTS:

Malvina B. Eydelman, MD Director, Division of Ophthalmic Device Evaluation FDA See bio on page 34

MODERATED BY:

Wiley A. Chambers, MD Supervisory Medical Officer, Division of Transplant & Ophthalmology Products FDA

Emmett T. Cunningham Jr. MD, PhD, MPH Partner Clarus Ventures See bio on page 32

See bio on page 32

2:50 - 3:20 PM SECOND ACTS - REINVENTING YOUR COMPANY The best ideas sometimes aren’t the ones that arrive early. A panel of experienced executives and investors will share how they have successfully turned obstacles into guideposts and transformed previously struggling companies into major successes.

PANELISTS:

Vicente Anido Jr., PhD CEO Aerie Pharmaceuticals See bio on page 26

MODERATED BY:

Mark Forchette Former CEO OptiMedica See bio on page 34

Thomas G. Frinzi President & CEO WaveTec Vision Systems See bio on page 36

Stuart Abelson President & CEO Ora See bio on page 26

Ron Kurtz, MD Founder Intralase See bio on page 42

3:20 - 3:50 PM AFTERNOON REFRESHMENT & NETWORKING BREAK

William J. Link, PhD Managing Director Versant Ventures See bio on page 42

a proud supporter of OIS

Enhancing Sight. Enhancing Lives.

LEADING THE WAY IN EYE CARE Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.

AGENDA

24 3:50 - 4:00 PM PRIVATE FUNDING TRENDS PRESENTATION Ophthalmology remains a popular target for private investors. Jon Norris, Managing Director of the Healthcare Practice at Silicon Valley Bank, will highlight recent financing trends.

Jonathan Norris Managing Director SVB See bio on page 48

4:00 - 4:10 PM THE OPTHALMOLOGY MARKET A View Of The Public Sector & Exit Trends Ophthalmology IPOs are on the rise. Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking at J.P. Morgan, shares how investors are viewing the sector.

Jeffrey Hoffman Managing Director & Head of West Coast Healthcare Investment Banking J.P. Morgan See bio on page 40

4:10 - 4:40 PM IPOS IN OPHTHALMOLOGY - THE CLASS OF 2014 AND BEYOND The IPO tide that swept through life sciences has enabled many eye care companies to set course for the public markets, providing new capital for companies and potential exiting opportunities for investors. Hear about what life is like on the public market and how other companies may follow the same path.

PANELISTS:

MODERATED BY:

Susan Washer Pesident & CEO AGTC See bio on page 54

Amarpreet Sawhney, PhD President & CEO Ocular Therapeutix See bio on page 52

Vicente Anido Jr., PhD CEO Aerie Pharmaceuticals See bio on page 26

Brian Johnson Partner WilmerHale See bio on page 40

Thomas W. Chalberg, PhD Founder & CEO Avalanche Biotechnologies See bio on page 30

Michael Gaito Managing Director, Head of West Coast Life Sciences J.P. Morgan See bio on page 36

David R. Guyer, MD CEO Ophthotech See bio on page 38

25

The Good, The Bad And The Unknown The consolidation of ophthalmology leaders is impacting innovation at all levels. Hear from the sector’s leaders about what the future might bring.

PANELISTS:

AGENDA

4:40 - 5:10 PM INDUSTRY CONSOLIDATION

MODERATED BY:

Jeff George President & Global Head Alcon See bio on page 38

David E.I. Pyott CEO Allergan See bio on page 50

Murthy V. Simhambhatla, PhD Ashley McEvoy President Company Group Chairman Abbott Medical Optics Johnson & Johnson Vision Care See bio on page 52 See bio on page 44

William J. Link, PhD Managing Director Versant Ventures See bio on page 42

James Mazzo Chairman & CEO AcuFocus See bio on page 44

5:10 PM WRAP-UP & CLOSING COMMENTS 5:10 - 6:30 PM COCKTAIL RECEPTION

Hosted By:

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

For more information regarding Shire, go to:

www.shire.com

SPEAKER BIOS

26 Stuart Abelson | President & CEO - Ora Stuart Abelson is President & CEO of Ora, Inc., the global leader in ophthalmic research and product development. He has been a Director since 1995 and served as the Company’s Chairman from 1997 until his appointment as President in 2007.

Mr. Abelson also serves as a Trustee at the Massachusetts Eye and Ear Infirmary, was a founder of Aciex Therapeutics and Entopica Therapeutics, and is a board member at Eye Therapies, LLC. Prior to joining Ora in an operating capacity, Mr. Abelson served in various management positions at Amphenol Corporation.

Noel Alpins, MD, FACS | CEO - Assort Dr Noel Alpins has been specialising in cataract and refractive surgery since founding NewVision Clinics in Melbourne in 1996. He speaks widely on these topics at national and international meetings. He has developed new techniques for treating and analysing astigmatism known as the Alpins Method which are journal published and described on Wikipedia and has developed the ASSORT array of surgical management computer programs for vector planning and analysis of treatment.

Noel is on the editorial board of several ophthalmic information magazines and peer reviewed journals. Noel is being presented with the ISRS/AAO lifetime achievement award at the coming ISRA/AAO meeting this week.

Vicente Anido Jr., PhD | CEO - Aerie Pharmaceuticals Dr. Anido was named Chief Executive Officer of Aerie Pharmaceuticals in July 2013 and was previously announced as Chairman of Aerie’s Board of Directors. He served as President and Chief Executive Officer of ISTA Pharmaceuticals from 2001 to 2012.

Prior, he was general partner of Windamere Venture Partners, served as President and CEO of CombiChem, Inc. and President of Americas Region of Allergan. Dr. Anido serves on the Board of Directors of Depomed Inc. He received an M.S. in Pharmacy Administration from West Virginia University and Ph.D. in Pharmacy Administration from the University of Missouri-Kansas City.

Laurent Attias | Head, Global Commercial Strategy - Alcon Mr. Attias has operational responsibility for commercial strategy across the Surgical, Pharmaceutical and Vision Care franchises. Before assuming his current role, Mr. Attias was President, Europe, Middle East and Africa (EURMEA). During his 18 years at Alcon, he progressed through the Sales and Marketing organizations by defining key strategic directions for the Surgical and Pharmaceutical franchises. Starting in 2002, Mr. Attias was VP, Refractive Sales and Marketing where he helped define Alcon participation in the Laser Refractive market. Prior to his move to Europe, he relocated to Toronto, Canada, where his operational contributions continued as VP/ General Manager of Alcon Canada.

Using the new ORA System® with VerifEye®+, it’s never been easier to set yourself up for better cataract outcomes.

That’s because ORA’s new dynamic reticle makes it simple to line up placement for toric IOLs and LRIs, while streaming refractive information allows you to refine your IOL power selection and determine the magnitude and axis of astigmatism with ease.

GIMME Power. Placement. Precision.

Win big using the enhanced ORA System with VerifEye+. Visit WaveTec Vision® Booth 538 at AAO to learn more. www.getorasystem.com

NEW IEC CLASS 1 LASER PRODUCT ORA System 2000 is marketed as the ORA System. The Intended use of the ORA 2000 System (ORA System or Optiwave Refractive Analysis) is to provide guidance to surgeons during cataract surgery. ©2014 WaveTec Vision. All rights reserved. WaveTec, WaveTec Vision, the WaveTec Vision logo, Optiwave, ORA System, the ORA System logo, and VerifEye are registered trademarks of WaveTec Vision. Data on file at WaveTec Vision. Individual results may vary. 80073 Rev D 08/14

Integrin Peptide Therapy for the Treatment of Vitreo-­Retinal Diseases Allegro Ophthalmics has one goal: to quickly, safely and cost-effectively bring to market new and improved treatment options for the leading causes of blindness.

Allegro’s novel Integrin Peptide Therapy treats vitreo-retinal diseases by targeting the integrin receptors involved in constructing new and aberrant blood vessels. By utilizing both anti-angiogenesis and vitreolysis, Allegro’s lead molecule, Luminate®, stops and reverses inflammation, vascular leakage, and neovascularization to restore vision.

Presently in Phase 2 studies, Luminate® has been shown to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema.

To learn more, visit www.allegroeye.com.

SPEAKER BIOS

28 Richard M. Awdeh, MD | Founder & CEO - CheckedUp Dr. Awdeh is a surgeon at the Bascom Palmer Eye Institute, the US News & World Report # 1 Ranked Eye Hospital in the US for the past 10 years. He received his BBA in Finance from Emory University, where he was Valedictorian, worked at Goldman Sachs, and earned his MD from Yale University. Dr. Awdeh completed his training at the Memorial Sloan Kettering Cancer Center in NYC and at Duke University. Dr. Awdeh is the founder of CheckedUp, a mobile healthcare application focused on strengthening doctor-patient communications. He is also the Founder of Cirle, a medical technology incubator.

Shelley Boyd, MD, FRCSC | President & CSO - Translatum Medicus Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina. She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California. She is director of the Ocular Phenotyping Facility of the Toronto Centre for Phenogenomics, and the Walter Retinal Regeneration laboratory. She is Assistant Professor of Ophthalmology & Vision Sciences, with cross-appointment to Biomedical Engineering, McMaster University. Shelley was formerly Head of the Ocular Angiogenesis Research Program, worldwide, with Novartis (Switzerland), overseeing pre-clinical and translational aspects of the Ranibizumab program.

Tom Brogan | Chairman of the Board - Vestrum Health

Tom Brogan developed the market for health claims data over 20 years ago through his company, Brogan, Inc. An economist by training, Tom’s unique data initiatives ultimately altered both the market research landscape and sales force incentive programs. Tom grew Brogan, Inc into a 160-person health economic and heath data research company that was sold to IMS Health in 2010, after which Tom was appointed VP Global Oncology at IMS Health. In 2014, Tom joined Vestrum Health to lead the development of Vestrum’s unparalleled clinical database and analytics platform that creates value for physicians, patients, and the healthcare industry.

Michael Brownell | CEO - Gobiquity Michael Brownell joined Gobiquity as CEO in 2012, with prior experience in a variety of leadership roles in ophthalmology and other industries. Gobiquity closed Series A financing with Interwest in July 2013. Michael was part of the initial management team at IntraLase, and at the time of acquisition by AMO he was VP of Product Development. While at AMO he had expanding responsibilities across multiple technology groups. Michael has an MS in physics and has held key roles at multiple start-ups, including Chief Technology Officer at Powerlase in the UK and VP of Product Development at GigaTera in Zurich.

Amakem corporate ad 7.5x4.62_awk_Layout 1 26/08/2014 08:37 Page 1

Think targeted...

...therapy for ophthalmology

Amakem’s goal is to target eye diseases with innovative therapies that are locally-active and therefore have fewer side effects Amakem’s lead product, AMA0076, is a novel highly potent locally-acting Rho Kinase (ROCK) inhibitor that has been designed to treat glaucoma by reducing intraocular pressure (IOP) while minimizing side effects.

In initial clinical trials, AMA0076 demonstrated IOP reduction without significant hyperemia: the first ROCK inhibitor to achieve this goal in the clinic.

www.amakem.com

SPEAKER BIOS

30 Robert Butchofsky | Founder & CEO - Mati Therapeutics Bob is the Founder and CEO of Mati Therapeutics Inc. He was previously CEO of QLT from 2005-2012. During that time, he modified the company’s strategy and focused the company in ophthalmology acquiring innovative new technology including the punctal plug drug delivery technology from ForSight Labs. He joined QLT in 1998 and was responsible for QLT’s marketing of Visudyne®. He was employed at Allergan from 1990-1998 and now serves as Chairman of the Board of both Superna Life Sciences Inc. and of CDRD Ventures. He has a BA degree in Biology from the University of Texas and an MBA from Pepperdine University.

Jeroen Cammeraat | CEO - i-Optics Jeroen Cammeraat is CEO of i-Optics and investor in the company since 2010.

A serial entrepreneur and senior executive with 20+ years of global experience in the medical technology and life sciences market. A former VP of Philips Electronics, where he joined the healthcare division in 1992. After 12 years with Philips he launched the European Discus Dental venture, a rapidly growing cosmetic dental company which was acquired by Philips in 2010. In 2010 Jeroen joined the global radiation therapy company Nucletron as COO where he led the successful management buy-out in 2007. Jeroen holds an MSc degree and an INSEAD MBA.

Ronen Castro | CEO - IOPtima

Ronen Castro is a seasoned medical device professional with 19 years of vast experience in the medical device industry. For the last 3 years prior to joining IOPtima, he was the CEO of Allium Medical Solutions (TASE:ALMD), a manufacturer of various MIS products. Previously, he served as the CEO of C-Boot, a manufacturer of advanced compression therapy products. For years he served in international marketing & sales and business development positions in few other Israeli medical device companies. He is also the founder of DCS Medical and EZ-Tube. Ronen Castro holds an MBA degree from Ben-Gurion University.

Thomas W. Chalberg, PhD | Founder & CEO - Avalanche Biotechnologies Dr. Chalberg is a co-founder of Avalanche and has been a member of the board since July 2006. He has also served as President and CEO since October 2010.

Prior to Avalanche, Dr. Chalberg worked at Genentech, where he held a number of roles in ophthalmology and oncology. From September 2001 to December 2005, Dr. Chalberg was a Howard Hughes Medical Institute Fellow at Stanford University, where his research focused on retinal diseases and new technologies for gene therapy. Dr. Chalberg is a member of the Board of Visionary Scientists for Hope for Vision, a nonprofit charity supporting vision research.

OPTIMIZE DRY EYE PATIENT CARE ENHANCE YOUR EYE CARE PRACTICE IMPROVE LIPID SECRETIONS, INCREASE COMFORT, SATISFY PATIENTS

LIPIFLOW®

LIPIVIEW®

Visit www.tearscience.com for complete product and safety information.

Surgical Management Systems HINDSIGHT • INSIGHT • FORESIGHT • Our aim is to guide ophthalmologists to improve surgical techniques and outcomes using unique analyses

• Our systems provide complete

Development of strategic relationships for international marketing and distribution The development team seeks to establish partnerships with equity potential in ASSORT®

confidentiality of reports

• The ASSORT systems can be networked within the clinic or for use by multiple clinic sites

Visit our OIS booth

USA: +1 (800) 345 1632 International: +61.3 9584 6966 enquiries@assort.com

Products include extensive international patent and trademark protection

www.assort.com en.wikipedia.org/Alpins method

SPEAKER BIOS

32 Wiley A. Chambers, MD | Supervisory Medical Officer, Division of Transplant & Ophthalmology Products - FDA Wiley A. Chambers, MD, is the Deputy Director of the Division of Transplant and Ophthalmology Products in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA). He is currently a Clinical Professor of Ophthalmology and Adjunct Assistant Professor of Computer Medicine at The George Washington University. He joined the FDA in 1987, as a primary reviewer for ophthalmic drug products and, in 1990, became a Supervisory Medical Officer, responsible for the clinical review of ophthalmologic drug products and ophthalmic therapeutic biologic products submitted to the FDA for study and potential approval.

Barry Cheskin | President & CEO - PowerVision Barry Cheskin is Co-Founder, President & CEO of PowerVision. Mr. Cheskin has 20 years of general management experience in the medical device business. Prior to PowerVision, he was President & CEO of medical device company, NanoGram Devices, which he sold to his largest competitor. Prior to that, he was President & CEO of minimally invasive cancer device company RITA Medical Systems, which he took public in 2000. Prior to that, he was Division President at medical device company, Datascope. He holds a B.S. and M.S. in Mechanical Engineering from MIT and Stanford, respectively, and an MBA from Columbia Business School.

Emmett T. Cunningham Jr., MD, PhD, MPH | Partner - Clarus Ventures

Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals. He helped build and lead the team that developed and commercialized Macugen. Prior to Eyetech, Dr. Cunningham was at Pfizer. His responsibilities included the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications. Dr. Cunningham is the founder and Chairman of the Ophthalmology Innovation Summit (OIS).

Robert Dempsey | Vice President & Business Unit Head - Shire Ophthalmics With more than 23 years of leadership experience the eye care space, Robert Dempsey joined Shire in February 2014 as Vice President and Head of Ophthalmology. He joined Shire from Bausch + Lomb as Executive Director, Pharmaceutical Medical Science North America. In that role, Robert served as a member of the Research & Development Leadership team, engaged in developing and supporting the overall medical strategy for commercially available products and pipeline assets. He worked closely to foster and enhance strategic relationships with Ophthalmic and Optometric thought leaders and support key medical affairs initiatives.

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,700 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and customers who rely on our products and the employees and communities in which we live and work.

For more information regarding Allergan, go to:

www.allergan.com

SV Life Sciences Advisers, LLC SV Life Sciences is a global leader in international life sciences investing. SVLS affiliated funds have been investing in life sciences companies since the early 1980s. The SVLS team manages five venture capital funds with approximately $2 billion of capital commitments. SVLS employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services.

One Boston Place Suite 3900 Boston, MA 02108 T: 617-367-8100 F: 617-367-1590

st

1700 Owens St, 1 Floor San Francisco, CA 94158 T: 650-571-8200 F: 650-571-8201 www.svlsa.com

WWW.SVLSA.COM

71 Kingsway London, WC2B 6ST United Kingdom T: 44-207-421-7070 F: 44-207-421-7077

SPEAKER BIOS

34 Dorit B. Donnoviel, PhD | Deputy Chief Scientist & Industry Forum Lead National Space Biomedical Research Institute Dr. Donoviel oversees the diverse portfolio of science and technology research and development projects at NSBRI that address the challenges faced by humans in space. She leads the NSBRI Industry Forum and the SMARTCAP seed award program for commercialization of biomedical technologies co-developed for both space and Earth-based markets. Dr. Donoviel is Director of the Laboratory for Biomedical Innovations where she evaluates emerging medical products that have the potential to transform medical care in space and on Earth. Dr. Donoviel is also an Assistant Professor in the Department of Pharmacology and Center for Space Medicine at Baylor College of Medicine.

Malvina B. Eydelman, MD | Director, Division of Ophthalmic Device Evaluation - FDA Dr. Eydelman joined the FDA in 1995 and for the last 17 years, has served as the Director of FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices (DOED), and subsequently Director of the FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices (DONED). Dr. Eydelman has been involved in all aspects of assuring the safety and effectiveness of ophthalmic medical devices. She also has been actively involved in standardization of ophthalmic devices as the U.S. Expert Delegate to the International Standards Organization and FDA’s Liaison to the American National Standards Institute‘s Committee for Ophthalmic Devices. award at the coming ISRA/AAO meeting this week.

Harvey Fishman, MD, PhD | Co-Founder & Medical Director - AppVisit

Dr. Harvey Fishman, M.D., Ph.D. is a Stanford-Trained Ophthalmologist, Diplomat of the American Board of Ophthalmology, and Fellow of the American Academy of Ophthalmology. He is the Founder and Former Director of the Stanford Ophthalmic Tissue Engineering Laboratory. Dr. Fishman has been published in numerous journals including Science, PNAS and The Archives of Ophthalmology. He holds ten Patents in the United States and is an invited speaker at International Ophthalmology Conferences. Dr. Fishman is also the Co-founder of AppMedicine, makers of AppVisit, a start-up specializing connecting patients with their providers on smartphones.

Mark Forchette | CEO - Delphinus Medical Technologies Mr. Forchette is an accomplished medtech executive with demonstrated success transforming industries and driving breakthrough technologies to market. Prior to Delphinus, Forchette was president and CEO of OptiMedica Corporation, leading the company through the company’s acquisition by Abbott Laboratories in 2013.

He began his career in medtech at Greishaber and Company, where he became VP of US sales and marketing, leading the company through its acquisition by Alcon. During his tenure at Alcon, he steered the tactical integration of Grieshaber, advanced to Vice President of vitreoretinal sales and global marketing, and led the retina portfolio through substantial market share gain.

www.avalanchebiotech.com

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sightthreatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.

Imagine a World Without Reading Glasses Introducing the FluidVision® lens, the first “true” accommodating IOL (intraocular lens) that could change the way middle aged and elderly individuals see the future.

Developed by PowerVision, this proprietary technology is poised to help millions with cataracts or Presbyopia (age-related loss of near vision) avoid reading glasses and bifocals.

• These fluid-based lens implants have been shown in early clinical studies of patients undergoing cataract surgery to deliver excellent near, intermediate and distance visual acuity.

• Lenses are implanted using standard surgical techniques, the way the vast majority of IOLs are implanted today – in the capsular bag.

Contact us to find out how FluidVision can potentially restore the vision of youth.

www.powervisionlens.com NOTE: The FluidVision® lens is an investigational device and it is not available for sale or use in the United States.

MKT06516 Rev A

For more information contact Matt Frinzi: 650.620.9948 x211 | mfrinzi@powervisionlens.com

SPEAKER BIOS

36 Doug Foster | CEO - DigiSight Doug Foster is CEO of DigiSight Technologies, a leading connectivity platform for mobile health technologies. DigiSight integrates a broad array of mobile technologies into clinical practice and believes that interoperability is the cornerstone for more efficient delivery of healthcare. Mr. Foster has over 15 years experience identifying and developing technologies for the healthcare industry. Prior to DigiSight, Mr. Foster was a Managing Director at Longitude Capital, a venture capital firm dedicated to the life sciences. Prior to Longitude, he worked at Pequot Ventures which was the private equity division of Pequot Capital. He was a member of the healthcare team and focused on structured financings for medical device and biotechnology businesses.

John Freshley | CEO - ONL Therapeutics John Freshley is the President and CEO of ONL Therapeutics having joined the company in July 2013. John is a serial entrepreneur with almost two decades of experience in leadership and founding roles of eight start-up companies with expertise in leadership team development, business strategy, business development and capital acquisition. Prior to ONL, John was Chief Business Officer of Compendia Bioscience through its acquisition by Life Technologies in 2012. John helped start the company in 2006 and served as its interim CEO. Previously, John had been President and CEO of Genetics Squared, a start-up focused on developing personalized oncology drugs.

Thomas G. Frinzi | President & CEO - WaveTec Vision Systems

Thomas G. Frinzi joined WaveTec as President and CEO in August 2010. Tom began his career at J&J and is a 30 year veteran of the ophthalmic and medical device industries. He served as VP of Global Commercial Operations at Bausch and Lomb Surgical. He held various executive roles at Refractec, including President, CEO and COO after an earlier role with Bausch and Lomb, where as Vice President of Sales, he managed numerous product launches with a focus on the growth and expansion of the ophthalmic market. His ophthalmic career also includes tenures at Chiron Vision Corporation, and Iolab Corporation.

Michael Gaito | Managing Director, Head of West Coast Life Sciences - J.P. Morgan Mr. Gaito is a Managing Director in J.P. Morgan’s Healthcare Investment Banking group responsible for the firm’s West Coast Life Sciences practice. He has been with J.P. Morgan and its predecessor firms for more than 18 years, beginning with Hambrecht & Quist’s Investment Banking group, focusing on the pharmaceutical industry. During this time, Mr. Gaito has advised clients on transactions representing more than $21 billion, with a focus on strategic advisory and financing assignments for biotechnology and pharmaceutical companies worldwide. Mr. Gaito received his AB degree from Princeton University and his MBA from Columbia University.

PAN

PTICA

SPEAKER BIOS

38 Jeff George | President & Global Head - Alcon Jeff George was appointed Global Head of Alcon in May 2014. Mr. George has held leadership roles across four divisions of Novartis since January 2007. Prior to assuming his current role, Mr. George led Sandoz, the second-largest generic pharmaceutical company globally and the third-largest Novartis division. Prior to this, Mr. George was Head of Emerging Markets for the Middle East, Africa, Southeast Asia, and CIS for Novartis Pharma. Mr. George holds an MBA from Harvard University and a master’s degree from Johns Hopkins University’s School of Advanced International Studies. He also holds a bachelor’s degree from Carleton College.

Bernhard Günther | CEO - Novaliq GmbH Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in ocular biopharmaceutics and medical devices. Prior to Novaliq, Mr. Günther served as CEO of Fluoron GmbH, pioneering the development of ophthalmic implants based on semifluorinated alkanes for the treatment of serious retinal diseases. At Fluoron, Günther was also responsible for the successful development and launch of the long-term endotamponade Densiron® 68 and the intraocular staining solution Brilliant Peel®. Mr. Günther served 10 years in leading senior management positions at Geuder AG. He also served as a Board Member of Fluoron GmbH.

David R. Guyer, MD | CEO - Ophthotech

David Guyer is CEO and Chairman of the Board of Directors of Ophthotech Corporation. He also serves on the boards of portfolio companies Allocure and PanOptica. Previously, Dr. Guyer, was a venture capitalist and Partner at SV Life Sciences. He has significant medical, drug development and commercial experience in ophthalmology. Following a career as Professor and Chairman of the Department of Ophthalmology at NYU School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc. Dr. Guyer received his Bachelor of Science degree from Yale College and his medical degree from Johns Hopkins Medical School.

William W. Hauswirth, PhD | Co-Founder - AGTC Dr. Hauswirth received his B.S. in Chemistry from Stanford University and his PhD in Physical Chemistry from Oregon State University. After an NIH Fellowship in the Biochemistry Department at Johns Hopkins University, he became an Assistant Professor. In 1976, he joined the faculty of Molecular Genetics and in 1985 the Ophthalmology faculty at the University of Florida. Dr. Hauswirth recently collaborated on the first successful rescue of a dominant genetic disease in animals and the first restoration of vision for a recessive retinal disease. His interests involve the delivery and testing of potentially therapeutic genes for Retinitis Pigmentos.

Shared Vision.

Endless Possibilities.

WilmerHale is honored to support the 2014 Ophthalmology Summit @ AAO.

wilmerhale.com

Š 2014 Wilmer Cutler Pickering Hale and Dorr llp

SPEAKER BIOS

40 Jeffrey Hoffman | Managing Director & Head of West Coast Healthcare Investment Banking - J.P. Morgan Jeff Hoffman is a Managing Director and Head of West Coast Healthcare Investment Banking at J.P. Morgan. He has more than 20 years experience in the full range of investment banking activities including financial advisory services, mergers and acquisitions, equity and debt financings, and venture capital investments. Prior to joining J.P. Morgan, Mr. Hoffman was Head of Healthcare Investment Banking at Piper Jaffray, with execution focus on life sciences and medical technology clients.

Mr. Hoffman received a BS in Psychology and an MBA from the University of North Carolina at Chapel Hill.

Henry Hsu, MD | Founder & CEO - Allysta Pharmaceuticals Henry Hsu, MD is the founder and CEO of Allysta Pharmaceuticals. He has been engaged in ophthalmic drug development for over 10 years. He was most recently the co-founder and CEO of Altheos, Inc., where he led business development negotiations and raised over $32 million to develop a novel ROCK inhibitor for glaucoma. Prior to that, Dr. Hsu served as Chief Medical Officer (CMO) of Molecular Partners and has held various CMO and clinical research positions of increasing responsibility at CoMentis, Co-Therix, Intermune and Chiron. Dr. Hsu received his medical degree from the University of California, San Francisco.

Brian Johnson | Partner - WilmerHale

Brian Johnson has extensive experience representing public and private companies and financial institutions, including investment banking clients, in a wide variety of corporate finance and other strategic transactions. He also advises clients on a regular basis on general corporate and securities law and governance matters. Mr. Johnson represents clients in a range of industries and has a particular focus on life sciences and emerging growth companies. He is the co-chair of WilmerHale’s capital markets practice group.

Vicken Karageozian, MD | Co-Founder & CTO - Allegro Ophthalmics Dr. Karageozian is the CTO and co-founder of Allegro Ophthalmics and has 15+ years of experience in ophthalmic drug development at Allergan, ISTA Pharmaceuticals, and Vitreoretinal Technologies. Dr. Karageozian has extensive experience authoring and leading US and international human clinical trials, including novel trial designs and clinical endpoint strategies, clinical and regulatory leadership, and corporate strategy decision making in first-in-class clinical programs.

He has been responsible for multiple Phase 2 and 3 studies involving hundreds of patients. Dr. Karageozian received his M.D. with Honors from Tufts University School of Medicine, and completed his ophthalmology residency at the University of California, Irvine.

&ODUXV 9HQWXUHV LV D JOREDO LQYHVWPHQW ILUP

GHGLFDWHG WR OLIH VFLHQFHV :H DSSURDFK KHDOWKFDUH LQYHVWLQJ ZLWK

SDVVLRQ IRU QRYHO LGHDV :H VWULYH WR JHQHUDWH RXWVWDQGLQJ

UHWXUQV IRU RXU LQYHVWRUV :H WKULYH RQ GLVFRYHULQJ LQQRYDWLYH SURGXFWV WR

LPSURYH people’s lives.

Emmett Cunningham, Jr., MD, PhD, MPH Nicholas Galakatos, PhD Dennis Henner, PhD Finny Kuruvilla, MD, PhD Jeffrey Leiden, MD, PhD Robert Liptak, MBA Michele Park, PhD Scott Requadt, JD, MBA Edward Scolnick, MD Nicholas Simon, MBA Michael Steinmetz, PhD Kurt Wheeler, MBA William Young, MBA

ZZZ FODUXVYHQWXUHV FRP

SPEAKER BIOS

42 Gilbert H. Kliman, MD | Managing Director - InterWest Partners Dr. Gil Kliman joined InterWest’s life sciences team in 1996. He invests in a broad array of life sciences opportunities with a special interest in ophthalmology and medical devices. He is a major investor in Epocrates (EPOC), Glaukos, IntraLase (ILSE), LenSx Lasers, Neuronetics, NeuroPace, On Demand Therapeutics, Restoration Robotics, and ReVision Optics. Prior to InterWest, Dr. Kliman was a healthcare investor at TA Associates and Norwest Venture Capital. As a practicing ophthalmologist he was the former west coast director of LCA Vision, and served on the clinical faculty at Tufts New England Eye Center and Massachusetts Eye and Ear Infirmary.

Ron Kurtz, MD | Founder - Intralase Ron Kurtz is an ophthalmologist and entrepreneur, having co-founded IntraLase Corp and LenSx Lasers Inc. He has also served on the Ophthalmology faculty at the University of California, Irvine, and at the University of Michigan. Dr. Kurtz earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.

Jesper J. Lange | President & Co-Founder - MC2 Biotek Group Mr. Lange joined MC2 Biotek Group as co-founder in 2007 from his position as partner in a major Danish law firm. In addition to his experience in M&A and commercialization of IPR, Mr. Lange has strong entrepreneurial and business skills, including expertise in commercialization of drug development projects. Mr. Lange holds Masters of Law (LLM) degrees from Columbia University Law School in New York and the University of Aarhus, Law School, Denmark. Mr. Lange is dedicated to develop MC2 Biotek Group as a network based entity bringing together the strongest expertise and diverse science and business experience to create attractive biotech projects.

William J. Link, PhD | Managing Director - Versant Ventures Bill Link specializes in early-stage medical device investing at Versant. Prior to cofounding Versant Ventures, he was general partner at Brentwood Venture Capital.

With extensive knowledge of medical devices, particularly in ophthalmology, his operating experience spans more than 23 years in general management. Bill has notable operational success in serving as founder, chairman and CEO of Chiron Vision, a subsidiary of Chiron Corporation specializing in ophthalmic surgical products, sold to Bausch and Lomb. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, sold to Allergan in 1986.

Developing the Next Generation of Science-driven AMD Therapies

Fovista®

Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet AMD.

Zimura™

Ophthotech’s second product candidate, Zimura™, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with Fovista® and anti-VEGF therapy for wet AMD. www.ophthotech.com

NASDAQ: OPHT

SPEAKER BIOS

44 John Maroney | CEO - ForSight VISION5 John Maroney is CEO of ForSight VISION5. John was a member of the Delphi Ventures for over ten years and continues his board relationship one of his portfolio companies. Prior to Delphi, John was President, CEO and Chairman of EndoTex Interventional Systems, which was acquired by Boston Scientific in 2007. John held a variety of senior management positions including President and General Manager at EP Technologies, VP of Operations at both Boston Scientific and Cardiovascular Imaging Systems (CVIS). While at CVIS, John was a member of the senior management team during the Company’s IPO and eventual acquisition by Boston Scientific.

James Mazzo | Chairman & CEO - AcuFocus James (Jim) Mazzo is Chief Executive Officer (CEO) of AcuFocus, and Executive Chair of Neurotech. Mr. Mazzo’s focus is on patient needs, new technology advancements and investment opportunities in the healthcare field worldwide. Previously, Mr. Mazzo assumed the position of Senior Vice President, Abbott Laboratories and President, Abbott Medical Optics following the company’s February 2009 acquisition by Abbott.

Prior to running the ophthalmic division for Abbott, he was Chairman and CEO of Advanced Medical Optics, Inc. after progressing through a 22-year career at Allergan.

Charlie McDermott | Interim President & CBO - Kala Pharmaceuticals Mr. McDermott has 20 years of operating experience in the biotechnology and ophthalmology industries and currently serves as Kala’s Interim President and CBO. Previously he served as Vice President of Business Development, Eye Care and Drug Delivery at Allergan, and established partnerships that ranged from novel platforms (DARPins, PEMs, siRNA, etc.) to commercial products such as Acular™, Acuvail™, Latisse™ and Lastacaft™. Before joining Allergan, Mr. McDermott worked deCODE Genetics and Agouron Pharmaceuticals in business development, drug discovery, and regulatory affairs roles. Mr. McDermott holds degrees in business (MBA), Molecular Biology (MA), and Biochemistry (BA).

Ashley McEvoy | Company Group Chairman - Johnson & Johnson Vision Care As company group chairman for Johnson & Johnson Vision Care, McEvoy leads one of the fastest-growing divisions of the global medical device segment. During her 17 years with J&J, McEvoy has worked with some of the company’s most powerful brands. McEvoy was previously worldwide President for Ethicon Products. Prior to joining Ethicon, she served as President of McNeil Consumer Healthcare. McEvoy joined Johnson & Johnson in 1996 as an assistant brand manager for Tylenol and Nicotrol. She became Vice President of marketing for McNeil’s consumer over-thecounter (OTC) business in 2003, and was promoted to General Manager of the OTC business in 2005 and President of McNeil Consumer Healthcare in 2006. Prior to Johnson & Johnson, McEvoy managed branding and advertising in Europe and the U.S. for Unilever and Procter & Gamble.

ForSight VISION5 is pleased to sponsor the Ophthalmology Innovation Summit.

We enjoy participating in this community of entrepreneurship and innovation, which is dedicated to helping patients see better. www.forsightvision5.com

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Our lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma. We are also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Our first product, ReSure速 Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

www.ocutx.com

AAO | Booth #2770

SPEAKER BIOS

46 Matthew J. McMahon, PhD | Director, Office of Translational Research, National Eye Institute - National Institutes of Health Dr. Matthew McMahon completed his graduate studies in retinal structure, function, and visual perception at the University of California, San Diego and performed postdoctoral research in primate retinal physiology at the University of Washington.

Previously serving as Senior Principal Scientist for Second Sight Medical Products and an AAAS Science and Technology Policy Fellow for the Senate Committee on Commerce, Science, and Transportation, he later served as professional staff on the House Science and Technology Committee. In his role at the National Eye Institute, Dr. McMahon facilitates translational research activities and participates in interagency initiatives.

David Muller, PhD | President & CEO - Avedro Dr. Muller recognized the potential of using advanced methods to gently reshape the cornea and in 2007 founded Avedro, Inc., where he serves as the CEO. Under his direction, Avedro has pioneered numerous advances in the field of crosslinking, including accelerated cross-linking, pulsed illumination, Lasik Xtra, and photorefractive intrastromal cross-linking (PiXL). He was the Chairman of the Board and CEO of Summit Technology and he is the author of publications in the areas of photochemistry and excimer laser development. In addition he is the inventor of numerous patents in the medical device field.

Nicholas Muzyczka, PhD | Co-Founder - AGTC

Dr. Muzyczka received his PhD in biochemistry from Johns Hopkins University in 1974. He became the founding Director of the University of Florida Powell Gene Therapy Center and oversaw the development of many of the standard techniques currently used to manufacture AAV vectors. In 2001, Dr. Muzyczka and his colleagues founded AGTC. He was the founding CEO and Chairman of AGTC, and continues to serve as a scientific consultant. He is an inventor on over 20 issued or pending patents and served on the Board of Directors of the American Society for Gene Therapy and the NIH Recombinant Advisory Committee.

Dan Myers | President & CEO - Alimera Sciences Dan Myers is the co-founder, President and CEO of Alimera Sciences, Inc. Alimera’s ILUVIEN®, is an intravitreal implant for the treatment of diabetic macular edema. Under Dan’s leadership, Alimera successfully completed an IPO in 2010 and ILUVIEN has now been approved in 11 countries including most recently, FDA approval last month. Dan has 30 years of sales, marketing and general management experience in the ophthalmic pharmaceutical industry through tenures at Novartis Ophthalmics, Allergan and Johnson & Johnson. Dan has served on numerous ophthalmic charitable boards and currently holds a seat on the Board of the Georgia BIO organization.

Extended Release Intravitreal Therapeutics Through Micro Particle Drug Delivery

www.graybug.com

SPEAKER BIOS

48 Jonathan Norris | Managing Director - SVB Jon Norris is a Managing Director with SVB Capital’s Venture Capital Relationship Management team, specializing in life sciences. Norris oversees strategic relationships with select life science venture capital firms on the West Coast, sourcing and advising on direct equity co-investment, limited partnership, and Portfolio Company banking and lending opportunities. In addition, he helps life science companies with equity fundraising strategy. Norris has more than eleven years of banking experience working with life science companies and venture capital firms.

Norris earned a bachelor’s degree in business administration from the University of California, Riverside and a jurist doctorate from Santa Clara University.

Franz Obermayr, PhD | Co-Founder & CEO - Panoptes Dr. Franz Obermayr is Co-founder and serves as Chief Executive Officer of Panoptes. Before that he was Head of Clinical Development at Nabriva, where he led the clinical efforts to show clinical POC in a phase 2b study leading to the successful Biotech-deal with Forest Laboratories. Before that he held several positions at GPC-Biotech where he led development programs in Germany and US and played a key role in commercialization these programs with pharmaceutical companies. Prior to GPC-Biotech he did his postdoctoral studies at the Max-Planck Institute for Immunobiology.

Michael O’Rourke | President & CEO - GrayBug Michael has 20 years of global ophthalmic leadership experience across pharmaceuticals, drug delivery and medical devices. He was appointed President & CEO of GrayBug in 2013, a new ocular pharmaceutical and drug delivery company developing new therapeutics in w-AMD and glaucoma. Previous experience includes General Manager for Bausch + Lomb Pharmaceuticals, Chiron Vision Europe, Alza, Pfizer and 3M Pharma. Michael has managed 26 brands, led 13 product launches, and has been a team member in 19 device/drug approvals. He is Foundation Board Chairman for Lions Eye Institute, the world’s largest Eye Bank with a unique Ocular Research Center.

Max G. Ostermeier, MBA | Co-Founder & General Manager Implandata Ophthalmic Products GmbH Max has extensive experience in the commercial development of technologically advanced products and in building operational capabilities for aggressively growing companies. As serial entrepreneur he was founder and CEO of several medical device start-up companies in Germany and the US and instrumental to proceed these companies to a successful exit. For close to 15 years now, Max is involved in the development of ophthalmic surgical products, working with leading institutes and researches in order to address currently unmet medical needs in eye care.

Brian P. Otis, PhD | Founder, Smart Contact Lens Project - Google X Dr. Brian Otis is the founder of Google [x]’s smart contact lens project. He received a B.S. in electrical engineering from the University of Washington, Seattle, and a M.S. and Ph.D. degree in electrical engineering from the University of California, Berkeley.

He joined the faculty of the University of Washington in 2005 where he runs a chip design research lab that designs tiny, low power chips.

...Developing a First-In-Class Versatile Platform for Continuous Delivery of Proteins to the Posterior Segment ...Pioneering the Use of a Genetically Engineered Proprietary Cell Line to Produce Targeted Therapies

...Proud to Be a Part of the Innovative Spirit of OIS 2014

SPEAKER BIOS

50 Quinton Oswald | President & CEO - Neurotech Quinton Oswald is the CEO of Neurotech. Prior to joining Neurotech, he served as the CEO of SARcode Bioscience, a San Francisco-based biotech that developed lifitegrast, an investigational product for dry eye disease. Previously, he was Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business. During his tenure at Genentech, Mr. Oswald directed the highly successful commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

David W. Parke, MD | CEO - American Academy of Ophthalmology Dr. Parke is CEO for the American Academy of Ophthalmology. Prior to assuming this role, Dr. Parke served for 17 years as president and chief executive officer of the Dean McGee Eye Institute, and Edward L. Gaylord Professor and Chair of the Department of Ophthalmology in the University of Oklahoma College of Medicine.

For 27 years he was a clinically active vitreoretinal surgeon, clinical investigator, and teacher. A graduate of Stanford University and an AOA graduate of the Baylor College of Medicine, Dr. Parke completed residency training at Baylor College of Medicine, serving as chief resident.

David E.I. Pyott | CEO - Allergan

David E.I. Pyott joined Allergan in 1998 and, during his tenure, has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company. Before joining Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG. Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.

Jane Rady | Divisional Vice President, Business Development Abbott Medical Optics Jane E. Rady is divisional vice president, business development at Abbott Medical Optics (AMO). Prior to AMO’s acquisition by Abbott in 2009, Ms. Rady was a corporate officer of Advanced Medical Optics. Prior to joining AMO, Ms. Rady was CEO of Integrated Genomics, Inc. and was a consultant to Integrated Genomics and several other companies. From 1984 to 2000, she was employed by G.D. Searle & Co. in various capacities. Prior to that, she headed venture investing activities in Monsanto focusing on emerging technologies and businesses in biotechnology. Ms. Rady began her career in Chicago with Abbott Laboratories.

About Morgenthaler Ventures. As active investors, we have partnered with some of the

world’s most visionary entrepreneurs. Morgenthaler Ventures is a premier venture capital firm with $3 billion under management. We have invested in more than 300 companies in the life science and information technology sectors.

Representative life science companies include: Ardian, OncoMed, Transcend, Nexis Vision, Promedior, Elcelyx, Holaira, Kona Medical, Moximed, Ra Pharmaceuticals, SetPoint Medical, Scioderm, Second Genome, and incubators The Foundry and ForSight Labs.

w w w.morgenthaler.com

SPEAKER BIOS

52 Calvin W. Roberts, MD | Executive Vice President & CMO - Bausch + Lomb Calvin W. Roberts, M.D. is Executive Vice President and the Chief Medical Officer at Bausch and Lomb. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics and innovative treatment regimens. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals. Dr. Roberts is a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a member of the board of directors of Alimera Sciences.

Paul Rubin, MD | CMO - XOMA Corporation Dr. Paul Rubin is XOMA’s SVP, Research and Development & Chief Medical Officer.

He joined the company in 2011. Prior to XOMA, Dr. Rubin was CMO at Funxional Therapeutics Ltd. He was CEO of Resolvyx Pharmaceuticals, Inc. and President and CEO of Critical Therapeutics, Inc. Prior to that, Dr. Rubin served as SVP, Development, and later as EVP, Research & Development at Sepracor. Additionally, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals and Abbott. Paul received a BA from Occidental College and his M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.

Amarpreet Sawhney, PhD | President & CEO - Ocular Therapeutix

Amarpreet Sawhney, PhD, is the President, CEO, and Chairman of the Board for Ocular Therapeutix. Dr. Sawhney was previously the founder and CEO of Confluent Surgical (acquired by Covidien), the Chairman of MarketRx (acquired by Cognizant), and technology founder of Focal, Inc. (acquired by Genzyme) and Access Closure Inc. (acquired by Cardinal Health). Dr. Sawhney’s innovations are the subject of over 120 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.

Murthy V. Simhambhatla, PhD | President - Abbott Medical Optics Murthy Simhambhatla, Ph.D., is Senior Vice President, Abbott Medical Optics, heading up the company’s global vision care business. Dr. Simhambhatla was appointed to this position in January 2013. Previously, he served as General Manager of the Ibis Biosciences unit of Abbott Diagnostics. Dr. Simhambhatla joined Abbott in 2006 through its acquisition of Guidant Corporation, as Divisional Vice President and General Manager for Drug Eluting Stents. He also served as General Manager for commercial operations in Australia and New Zealand for Abbott Vascular. Before joining Guidant, Dr. Simhambhatla worked in research and development at Raychem Corporation in Menlo Park, CA.

build winning technology and healthcare companies. We have a long-standing

including AGTC, Glaukos, Gobiquity, IntraLase (acquired by AMO), LenSx (acquired

turn their ideas into a thriving company. www.interwest.com A G T C

INDICATION Mitosol® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

Dosage & Administration Mitosol® is intended for topical application to the surgical site of glaucoma filtration surgery and must be reconstituted prior to application. Sponges provided within the Mitosol® Kit should be fully saturated with the entire reconstituted contents in a manner prescribed in the Instructions For Use. The sponge(s) should be applied to the treatment area for two minutes.

Reconstituted Mitosol® should be used within one hour of reconstitution.

IMPORTANT SAFETY INFORMATION Contraindications Mitosol® is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin, and in women who are or may become pregnant during therapy.

Warnings & Precautions Cell Death, mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death.

Hypotony. The use of mitomycin has been associated with an increased instance of post-operative hypotony.

Cataract Development. Use in phakic patients has been correlated to higher instance of lenticular change and cataract formation.

Adverse events and reactions The most frequent adverse reactions to Mitosol® occur locally and include hypotony, hypotony maculophathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract.

Mitosol ® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use

BLIND FAITH

Isn’t What You Learned in Medical School Compounded mitomycin degrades rapidly1.

So what you want and what you get could be a shot in the dark.

Mitosol® is reconstituted on the sterile field at the time of use.

So it’s right on the mark every time2.

Eliminate one more variable from your surgery.

Choose Mitosol®.

Compliance. Containment. Consistency. Cost.

Mitosol®: The Choice is Yours.

Get More Information at www.mobiustherapeutics.com 1-877-EYE-MITO (1-877-393-6486) 1 Degradation of Mitomycin Under Various Storage Conditions; Kinast RM, Mansberger SL; Poster 83-111; AGS 2014 2 Data on file; Mobius Therapeutics, LLC and US Food and Drug Administration; NDA #22-572

For brief prescribing information visit www.mobiustherapeutics.com.

2014 0007

SPEAKER BIOS

54 Ed Timm | President & CEO - Mobius Therapeutics Ed has more than 25 years experience in the surgical device/life science industry.

He has initiated and/or grown sub-specialty franchises for multiple companies, to include American Hospital Supply Corporation, Applied Medical Resources, Storz Ophthalmics, and Given Imaging, Ltd.. Most notably, he was responsible for Commercial Development at Synergetics, Inc., taking the company from start up status to a M$40 public company, operating successfully in sixty countries and two surgical disciplines. Mr. Timm holds a B.A. degree in Philosophy from the University of Dayton and is the holder of seven issued US patents, with numerous patents pending.

Russell Trenary | President & CEO - InnFocus Russ Trenary is President & CEO for InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma. He has led, or been a named officer, for medical device companies, for over 20 years. His managerial experience includes specific interfacing in Marketing / Sales / Finance / R&D / Clinical / Regulatory / Manufacturing. He has turned unprofitable $100MM divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at AMO (NYSE:EYE). He also has vast experience with large volume product launch and company acquisitions.

Susan Washer | President & CEO - AGTC Sue Washer, President and CEO of AGTC, is an experienced entrepreneur with a strong scientific and operational background. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida. Sue has 10 years of management and research experience with Abbott and Lilly. At Abbott Ms. Washer led teams bringing new products and technologies from the lab bench into the marketplace. Ms. Washer has 16 years of senior management experience with entrepreneurial firms. At AGTC, Ms. Washer has successfully raised over $43M and led a collaboration with a top five Biotech.

Tim Willis | Co-Founder & CEO - TearScience Mr. Willis has more than 35 years of medical device industry experience. Tim is an entrepreneur and inventor and has been responsible for the development and launch of 50+ products that today represent over a half billion dollars in annual sales. He has served as senior management, R&D, marketing, and corporate and business development at several leading healthcare corporations. Tim is a scientist and engineer who sits on the Board of TearScience, Life Branch Institute and Trinity Academy. He is a member of the ASCRS, ARVO, and Licensing Executive Society and a Fellow of the American Academy of Optometry.

Imagine that the power to beat genetic disease is within us.

AGTC is a clinical stage biotechnology company developing novel systems to deliver human therapeutics. Our team exceeds expectations every day, placing a high standard on integrity and open communication in all areas of our business enterprise.

We are always looking for technical and business professionals who are eager to have a significant impact on improving patient care. If you are highly self-motivated; comfortable working as part of a cross-functional team; enjoy interdisciplinary problem-solving; and want to work in an extremely dynamic and fast-paced environment, then you may be a great fit on our team.

AGTC is an equal-opportunity employer, offering competitive cash and stock-based compensation, excellent employee benefits and tremendous opportunity for personal and professional growth in an outstanding and intellectually-challenging work environment. Competitive compensation is offered commensurate with education and experience of the successful candidate, including salary, benefits, and company equity. AGTC is an EOE and maintains a drug free workplace.

Visionary science for life changing cures.

For information on all current opportunities, please visit our website at www.agtc.com/careers.

11801 Research Drive, Suite D • Alachua, FL 32615

TOTAL CORNEAL ASTIGMATISM

Interested in improving your toric and LRI outcomes ?

Measuring Posterior Astigmatism ? i-Optics releases new Cassini Corneal Shape Analysis functionality to measure both anterior and posterior astigmatism, providing refractive-cataract and cornea surgeons with a Total Corneal Astigmatism (TCA) measurement.

Meet us at the

Cassini 3°

1

2

Placido 13° 3 Scheimpflug 30°

BOOTH

OIS-AAO #1671

For more information: Call us at 888-660-6965.

Contact us at usa@i-optics.com Or visit www.i-optics.com

Cassini TCA - Premium treatment starts with premium diagnosis!

1 : A. John Kanellopoulos, MD. Clinical Professor Of Ophthalmology, New York University Medical School - Submitted. 2 : Karabatsas et al. BJO 2005. 3 : McAlinden et al. IOVS 2011

ARE YOU AN INNOVATOR? IS YOUR VOICE BEING HEARD?

“

I find myself logging on to ShoutMD on a daily basis. Unique to this site is communication between surgical specialists in multiple fields outside ophthalmology and the active participation of brilliant minds in business, finance and practice management. ShoutMD is destined to be my favorite media site, and is already a game changer in medical blogs. I recommend without reservation active participation to all my colleagues who are eligible.

“

Richard Lindstrom, MD Board Certified Ophthalmologist

JOIN THE CONVERSATION

BE A PART OF SHOUTMD ShoutMD is the first “Procial,” professional and social, community designed exclusively for board certified specialists to share new insights, discuss the latest research and collaborate with peers to improve patient experiences and outcomes.

DOWNLOAD SHOUTMD TODAY Text the word Shout to 74121 to download the app or visit www.shoutmd.com.

Š2013, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591

Innovative Nanotechnology Delivery Kala Pharmaceuticals, Inc. is advancing innovative nanoparticlebased treatments for ocular diseases by enhancing local drug delivery with its proprietary MucusPenetrating Particle (MPP) platform.

www.Kalarx.com

All rights reserved

09/2013

RGN-0108

Think Low. The next small thing in glaucoma surgery. www.InnFocusInc.com

INNF-12918 OIS at AAO 2014 Ad r3.indd 4c www.mc2biotek.com

10/1/14

— 7.5” x 4.625”

0 N/A

INTRODUCING ™ PADciclo - BECAUSE TOLERABILITY MATTERS Preservative free, unit dose, once daily ciclosporin eye drop

PAD™ Technology – releasing the full potential of API’s

59

Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. AMO is headquartered in Santa Ana, California, employing approximately 4,000 worldwide. www.abbottmedicaloptics.com

AcuFocus | Strategic Sponsor AcuFocus is the leader of small aperture optics, focusing on technologies to improve near vision for presbyopic patients. AcuFocus is the exclusive global distributor of the AcuTarget HD™ diagnostic and surgical planning instrument providing practices objective data to support patient selection, proper centration for approved inlays and post-operative management. www.acufocus.com

Aerie Pharmaceuticals | Major Sponsor Aerie is a clinical-stage pharmaceutical company with a focus on glaucoma therapies. Aerie commenced two Phase 3 registration trials in the US for triple-action Rhopressa™ named “Rocket 1” and “Rocket 2, a third Phase 3 safety trial, named “Rocket 3,” in Canada and a Phase 2b clinical trial for quadruple-action Roclatan™.

SPONSOR PROFILES

Abbott Medical Optics | Exclusive Sponsor

www.aeriepharma.com

AGTC | Supporting Sponsor AGTC uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC’s lead product candidates focus on orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. www.agtc.com

Alcon | Major Sponsor Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people see better. The three Alcon businesses - Surgical, Pharmaceutical and Vision Care - offer the widest spectrum of eye care products in the world. Alcon’s the second largest division of Novartis. www.alcon.com

SPONSOR PROFILES

60 Alimera Sciences | Supporting Sponsor Alimera Sciences is a pharmaceutical company focused on diseases affecting the retina. Its product, ILUVIEN® (fluocinolone acetonide intravitreal implant) has received marketing authorization for chronic diabetic macular edema considered insufficiently responsive to available therapies in Austria, Denmark, France, Italy, Norway, Portugal and Spain, and has been launched in Germany and the UK. www.alimerasciences.com

Allegro Ophthalmics | Supporting Sponsor Allegro quickly, safely and cost-effectively bring to market new and improved treatment options for the leading causes of blindness. In only four years, Allegro has progressed Luminate® from drug discovery, to establishing safety and initial efficacy in both animals and human patients, to phase 2 clinical trials in DME and vitreomacular traction. www.allegroeye.com

Allergan | Strategic Sponsor Allergan is committed to uncovering the best of science by developing and delivering innovative and meaningful treatments to help people reach their life’s potential.

Allergan has a presence in more than 100 countries, a rich and ever-evolving portfolio, and state-of-the-art resources in R&D, manufacturing and safety surveillance. www.allergan.com

ALPHAEON | Major Sponsor ALPHAEON is a lifestyle healthcare company committed to partnering with boardcertified physicians to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. Alphaeon fosters deep relationships with leading specialty physicians so patients receive the best in lifestyle healthcare. www.alphaeon.com

Amakem Therapeutics | Supporting Sponsor Amakem Therapeutics is a clinical-stage ophthalmology company developing innovative treatments for serious eye conditions. The Company’s goal is to create therapies based on its “Localized Drug Action” platform, minimizing systemic exposure and reducing side effects. Amakem’s lead product, AMA0076, is designed to treat glaucoma by reducing intraocular pressure while minimizing side effects. www.amakem.com

61

ASSORT ® is an ophthalmic software manufacturer based in Melbourne, Australia and founded by ophthalmologist Dr Noel Alpins in 1992. The ASSORT® suite of products, which are designed for use in planning and analysing cataract and refractive surgery, have extensive international patent and trademark protection. www.assort.com

Avalanche Biotechnologies | Strategic Sponsor Avalanche, a clinical-stage biotechnology company, discovers and develops novel gene therapies to treat sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, Avalanche provides long-term benefits or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. www.avalanchebiotech.com

Avedro | Premier Sponsor Avedro is a privately held medical device and pharmaceutical company developing corneal cross-linking, a non-invasive treatment for refractive disorders and certain pathologies. Avedro sells in 62 countries and recently submitted an NDA to the FDA. Avedro is also developing, Photorefractive Intrastromal Cross-Linking (PiXL™), for post-cataract ametropia and refractive correction. www.avedro.com

Bausch + Lomb | Strategic Sponsor Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including contact lenses and lens care products, pharmaceuticals, intraocular lenses and other eye surgery products. www.bausch.com

Clarity Medical Systems | Strategic Sponsor Clarity Medical Systems is a medical device company that develops, manufactures and markets integrated optical systems and services to enhance the clinician’s ability to diagnose, manage, and treat eye disorders. These patented devices combine innovative optical, electronic and information technologies, changing the very nature of the provision of eye healthcare. www.claritymsi.com

SPONSOR PROFILES

Assort | Supporting Sponsor

SPONSOR PROFILES

62 Clarus Ventures | Founding Sponsor Clarus Ventures is a global investment firm dedicated to life sciences. The deep domain expertise of the Clarus team allows us to employ a hands-on philosophy of providing value enhanced leadership and guidance in working with our management teams in both the biopharmaceutical and medical device arenas. www.clarusventures.com

Eleven Biotherapeutics | Supporting Sponsor Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a protein engineering platform, called AMP-Rx. Eleven’s approach uses insights into the structural biology of cytokines and their role in diseases of the eye. Eleven’s, EBI-005, is in clinical development as a topical treatment for dry eye disease and allergic conjunctivitis. www.elevenbio.com

ForSight VISION5 | Supporting Sponsor ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. www.forsightvision5.com

Genentech | Premier Sponsor Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. www.gene.com

GrayBug | Supporting Sponsor GrayBug has developed a technology to reduce the frequency of treatment injections to every 4 to 6 months, reducing risks associated with repeated intraocular injections. In addition, GrayBug is applying its novel technology to a lead compound that blocks both key pathways of neovascularization in w-AMD, VEGF and PDGF. www.graybug.com

63

SPONSOR PROFILES

iCo Therapeutics | Strategic Sponsor

iCo Therapeutics has exclusive rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies. With Phase 2 clinical history, iCo-008 is targeted for the treatment of vernal or atopic keratoconjunctivitis and wet age-related macular degeneration. www.icotherapeutics.com

IDDI | Supporting Sponsor IDDI’s mission is to optimize the clinical development of drugs, biologics and devices using innovative integrated eClinical technologies with expert methodology in biostatistics to optimize the design, conduct and data analysis of clinical trials. www.iddi.com

InnFocus | Supporting Sponsor InnFocus MicroShunt ™ addresses the largest glaucoma patient segment and has achieved mean post op IOP’s below 14 mm Hg, and 80% med reduction. IOP reduction at 3 months similar to 3 year. By 12/31/14, over 20 doctors will have treated over 150 patients, followed for up to 3 years. www.infocusinc.com

InterWest Partners | Founding Sponsor For over 30 years InterWest has partnered with entrepreneurs to build winning technology and healthcare companies. With over 200 years of combined operating and investing experience, the InterWest team believes providing capital is just the beginning of a longterm collaboration with entrepreneurs to turn their vision into a thriving company. www.interwest.com

i-Optics | Strategic Sponsor i-Optics pioneers smart and superior eye diagnosis solutions that are affordable, fast and user-friendly for care providers worldwide. Their innovations include: Cassini – A first-of-its-kind Corneal Shape Analyzer, EasyScan – A breakthrough, zero-dilation retinal imaging system to diagnose retinal diseases, and EyePrevent –An effective and cost-efficient retinal disease screening service. www.i-optics.com

SPONSOR PROFILES

64 Kala Pharmaceuticals | Supporting Sponsor Kala Pharmaceuticals, Inc. is advancing innovative nanotechnology-based treatments for ocular diseases with significant unmet needs in both front and back of the eye.

Kala leverages the company’s proprietary Mucus Penetrating Particle platform technology to develop topical ophthalmic formulations that enhance ocular tissue exposure by facilitating penetration through the mucus layer. www.kalarx.com

MC2 Biotek Group | Supporting Sponsor The privately held MC2 Biotek is using its unique and patented oil-in-water dispersion - PAD™ Technology - in the ophthalmic and dermatological fields. PAD™ Technology enables release of the full potential of API’s and is the basis for comfortable and patented topical drugs that will improve patient compliance and clinical benefits. www.mc2biotek.com

Mobius Therapeutics | Supporting Sponsor Mobius Therapeutics™ believes that retasking of molecules is more efficient than drug discovery. Standard of care indications creates NDA’s with less burdensome provisions.

The resulting entity creates 6 products in multiple subspecialties. Revenues fund new solutions to existing problems for evolving products and procedures. www.mobiustherapeutics.com

Morgenthaler Ventures | Founding Sponsor Morgenthaler Ventures, a premier venture capital firm with $3 billion under management, invested in over 300 companies in life sciences and information technology - Ardian, OncoMed, Transcend, Nexis Vision, Promedior, Elcelyx, Holaira, Kona Medical, Moximed, Ra Pharmaceuticals, SetPoint Medical, Scioderm, Second Genome, and incubators The Foundry and ForSight Labs. www.morgenthaler.com

Neurotech | Supporting Sponsor Neurotech Pharmaceutical’s core technology, Encapsulated Cell Therapy (ECT), is a proprietary first-in-class drug delivery platform for the treatment of chronic eye diseases. The ECT implant enables continuous immune-privileged production and delivery of therapeutic proteins, derived from a customized cell line, for at least two years to the posterior segment. www.neurotechusa.com

65

Novaliq GmbH, based in Heidelberg, is a drug delivery company that is developing a superior generation of innovative ocular formulations for poorly soluble drugs. The patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be easily applied in the form of topical eye drops. www.novaliq.de

Ocular Therapeutix | Supporting Sponsor Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The Company is currently evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved. www.ocutx.com

ONL Therapeutics | Supporting Sponsor ONL Therapeutics preserves vision through the protection of photoreceptors from retinal disease. ONL is developing ONL-101, a small injectable peptide that blocks photoreceptor apoptosis. Initial development targets retinal detachment with a neoadjuvant therapy at time of diagnosis and prior to surgery. Further development will protect photoreceptors until the disease is stabilized. www.onltherapeutics.com

Ophthotech | Strategic Sponsor Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration. Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with antiVEGF drugs. www.ophthotech.com

Ora | Exclusive Sponsor Ora is the world’s leading independent, full-service ophthalmic research and product development firm. Over the past 30 years, Ora has helped their clients earn 37 FDA approvals. Ora supports a wide array of organizations to efficiently and successfully bring their new products from concept to market. www.oraclinical.com

SPONSOR PROFILES

Novaliq GmbH | Supporting Sponsor

SPONSOR PROFILES

66 Pacific Eye Institute | Supporting Sponsor Pacific Eye Institute has provided quality eye care to the Inland Empire since 1981.

The Pacific Eye Institute has been on the forefront of vision correction procedures including treatment for glaucoma, cataracts, and macular degeneration. In addition, the Pacific Eye Institute has been a leader in Lasik since 1996. www.pacificeyelaser.com

PanOptica | Supporting Sponsor Co-Founders, Paul Chaney and Martin Wax, MD, are recognized leaders in the search, evaluation, licensing, development and commercialization of ophthalmic pharmaceuticals. PAN-90806 is a novel topically administered VEGF antagonist for the treatment of neovascular AMD. PanOptica’s currently enrolling patients in a doseranging phase 1/2 study, testing safety and biological response. www.panopticapharma.com

PowerVision | Supporting Sponsor PowerVision, Inc. has developed a proprietary fluid-controlled accommodating intraocular lens (IOL) technology designed to restore youthful vision to millions of middle aged or elderly individuals. The Company has proven in recent clinical trials that it can deliver clear near, intermediate and distance vision with its fully injectable accommodating device. www.powervisionlens.com

Regeneron | Major Sponsor Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical needs. www.regeneron.com

Shire Ophthalmics | Strategic Sponsor Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology. www.shire.com

67

SV Life Sciences is a global leader in healthcare investing. SVLS employs a diversified strategy within healthcare and generally targets early stage opportunities in biotechnology, a combination of early and expansion stage deals in medical devices and growth equity opportunities within the healthcare services and healthcare information technology segments. www.svlsa.com

TearScience | Supporting Sponsor TearScience® has pioneered ophthalmic procedures and devices that identify, diagnose and treat evaporative dry eye. The TearScience® in-office Dry Eye Solution includes the SPEED© Dry Eye Questionnaire, Korb MGE™, LipiView® Ocular Surface Interferometer and LipiFlow® treatment device along with a simplified implementation plan, practice marketing tools, and proven procedure support. www.tearscience.com

Translatum Medicus | Supporting Sponsor Translatum Medicus inc (TMi) de-risks and accelerates drug development for dry Age Related Macular Degeneration. TMi’s technologies include a pre-clinical model that mimics advanced dry AMD and aligns with clinical trial endpoints, and TMi-018, that dose-dependently protects against RPE loss. TMi-018 is safe in clinical studies for non-ophthalmic indications.

SPONSOR PROFILES

SV Life Sciences | Founding Sponsor

www.translatummedicus.com

Versant Ventures | Founding Sponsor Versant Ventures is a leading venture capital firm specializing in investments in gamechanging biopharmaceutical and medical device opportunities. Versant pioneered the build-to-buy structured exit model, creating new companies based on insights and knowledge. The experienced team of investors is committed to helping entrepreneurs build developing breakthrough therapies successful companies. www.versantventures.com

WaveTec Vision Systems | Supporting Sponsor WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. Our revolutionary ORA System® provides intraoperative refractive information to ophthalmologists worldwide, allowing them to deliver the best possible vision for their cataract patients. www.wavetecvision.com

SPONSOR PROFILES

68 WilmerHale | Supporting Sponsor WilmerHale represents industry leaders in biotechnology, pharmaceuticals, medical devices and beyond in confronting and resolving challenges. From companies at all stages of growth to venture capitalists and investment banks, WilmerHale understands the business of our life sciences clients and the changing regulatory, competitive and consumer demands that the industry faces. www.wilmerhale.com

XOMA | Supporting Sponsor XOMA’s portfolio of innovative product candidates is the result of the Company’s focus on allosteric modulation, which offers opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis, and ongoing studies in other IL-1-mediated diseases. www.xoma.com

Translatum Medicus Inc (TMi) de-risks and accelerates drug development for dry Age Related Macular Degeneration. TMi’s technologies include a pre-clinical model that mimics advanced dry AMD and aligns with clinical trial endpoints, and TMi-018, that dosedependently protects against RPE loss. TMi-018 is safe in clinical studies for non-ophthalmic indications.

For more information regarding Translatum Medicus Inc, go to:

www.translatummedicus.com

7TH ANNUAL

O UNITING OVER 800 LEADERS

in the Development of Ground-Breaking Ophthalmic Technologies

35+30+20105 10%

5%

35%

NOVEMBER 12, 2015 LAS VEGAS, NV

20%

30%

2014 Attendee Demographics Physicians Industry/Corporate Executives Private Ophthalmic Companies Finance/Investment Press/Media

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.

OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

WWW.OIS.NET/AAO2015

DON’T GET CAUGHT IN

THE CROSSROADS EyeNet publications keep you in step

Meeting News with Soul FOLD-OUT COVER

Exhibition Hall Map

Academy Exhibitors THE GUIDE TO

While in Chicago,

Destination AAO 2014 get ready for chicago : part 1

BEAT THE CLOCK

Avoid the long lines at the Registration area in New Orleans. Go online now to register for the following meetings: • Subspecialty Day (Nov. 15-16), • the AAOE half-day coding meetings (Nov. 16), or • the Annual Meeting (Nov. 16-19).

Register by Oct. 2 to have your badge and registration materials mailed to you before the Annual Meeting.

From Oct. 3 to 23, you can still register online, but you will need to pick up your badge and other meeting materials onsite.

After Oct. 23, you must register at the Morial Convention Center. The Academy Plus course pass, most ticket prices, and Subspecialty Day fees increase onsite.

Register now. Go to www.aao.org/ registration.

be sure to tune in to

n Notify the Academy if You

Need Special Assistance

’s meeting

are instrumental to staying informed about meeting-related

Visit us at the AAO 2014 Publishers’ Row and at www.eyenet.org.

12

a p r i l

2 0 0 9

Seven Meetings to Explore

55 Beat the Clock

57 Hall Highlights

55 Program

cialty Day session that takes place that day. If you register for a two-day meeting, you also can attend any session from either of Friday’s Subspecialty Day meetings.

n Subspecialty Day: You Have Subspecialty Day opens on Friday, Nov. 15, with two meetings—Refractive Surgery and Retina. It gets into full swing on Saturday, Nov. 16, with the addition of five more meetings— Cornea, Glaucoma, Neuro-Ophthalmology, Oculofacial Plastic Surgery, and Pediatric Ophthalmology.

Explore all seven meetings. If you register for one of the Saturday-only meetings, you can attend any Subspe-

n Program Directors Preview

the Peds and Retina Meetings

This month, program directors for the Pediatric Ophthalmology and Retina Subspecialty Day meetings share some of this year’s highlights. To see the full schedules, go to www.aao.org/2013 and click “Subspecialty Day.” (See July’s EyeNet at www.eyenet.

55

e y e n e t

ACADEMY LIVE

Four daily e-newsletters with onsite reporting bring you the meeting’s clinical highlights.

page

4

An Insider’s Guide to Subspecialty Day

26 presentations you won’t want to miss.

10

page

22 EHR Exhibitors

Read this before visiting them.

GUIDE TO ACADEMY EXHIBITORS Comprehensive

exhibitor listings, map, and contact information.

18

page

Best Practices in Patient Education

Why you should update your handouts.

FIRST EDITION WITH A FOCUS ON

FRIDAY & SATURDAY

page

6

Q&A With the Academy Laureate

How to become a successful pioneer.

news and events.

PROGRAM

The Academy wishes to ensure that no individual with a disability is excluded or denied services, segregated, or otherwise treated differently from other individuals because of the absence of auxiliary aids or services.

If you need any of the auxiliary services identified in the Americans With Disabilities Act, e-mail the Academy at meetings@aao.org.

13

page

Imaging Devices

Be DICOM-savvy when shopping.

16

page

ICD-10: Get Up to Speed Fast

Use this at-a-glance resource.

OCTOBER EYENET

Part Six of Destination AAO 2014 gives a quick rundown of meeting essentials, plus a summary of what’s new this year.

ACADEMY NEWS A two-issue convention hall tabloid available Friday, Oct. 17, and Sunday, Oct. 19.

SECOND EDITION WITH A FOCUS ON

SUNDAY, MONDAY & TUESDAY

photo credit

publications. They

n Make the Most of your tiMe in the exhibit hall.

The Annual Meeting features the world’s largest exhibition screenshot of Online Proof ophthalmic technology, gram search, tk tk tk products, and services—and you can use the Virtual Exhibition to zero in on those exhibitors that will be most useful to your practice. use the Virtual exhibition to plan ahead. Go to www.aao. org/2013 and select “Exhibition” from the left navigation bar. Choose your search criteria to locate exhibitors by company name, booth number, product categories, or the ophthalmic subspecialty they relate to—or simply type a term into the search field—and the relevant exhibitors will be circled on the map (see screenshot). Next, click on an exhibitor to review its digital booth.

Create a “My expo” account. If you would like to print a personalized map of exhibitors, first visit the Virtual Exhibition and create a “My Expo” account by entering your e-mail address and choosing a password. Then you can tag the exhibitors you plan to visit and click “Print.”

n Register Now to Avoid Standing in Line Later

New HorizoNs Forum REGISTER NOW www.glaucoma360.org

February 6, 2015

The Palace Hotel – San Francisco, CA

Speeding the development of new therapies and diagnostics for glaucoma patients Keynote Speaker: Paul P. Lee, MD, JD

Chair of Ophthalmology and Visual Sciences; Director, W.K. Kellogg Eye Center, University of Michigan

“This is the glaucoma meeting to attend.”

–George A. Cioffi, MD Chairman of Ophthalmology, Columbia University of Physicians and Surgeons

251 Post Street, Suite 600, San Francisco, CA 94108 – (415) 986-3162 – www.glaucoma360.org

4TH ANNUAL

UNITING OVER 400 LEADERS

in the Development of Ground-Breaking Ophthalmic Technologies

25+25+3010 10%

HILTON SAN DIEGO BAYFRONT

APRIL 16, 2015 SAN DIEGO, CA

10%

30%

25%

25%

2014 Attendee Demographics Physicians Industry/Corporate Executives Private Ophthalmic Companies Finance/Investment Press/Media

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.

OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

WWW.OIS.NET/ASCRS2015

6:30 - 7:30 AM Registration Check-in & Breakfast 7:30 - 7:45 AM Welcome & Chairman’s Opening Remarks 7:45 - 9:37 AM BioPharma Company Showcase 9:37 - 10:07 AM Networking Break 10:07 - 11:51 AM Device, Delivery & Diagnostic Company Showcase 11:51 - 12:21 PM Digital Ophthalmology Showcase 12:21 - 12:41 PM Digital Ophthalmology: The Alcon/Google Partnership & Beyond 12:41 PM Luncheon Commences 1:10 - 1:35 PM Plenary Keynote: Accelerating Innovation In Ophthalmology 1:35 - 2:00 PM OIS Innovator Award Presentation 2:00 PM Luncheon Concludes 2:00 - 2:07 PM Ophthalmic Innovation 2014 – “A View From The AAO” 2:07 - 2:15 PM Ophthalmic Innovation 2014 – “A View From The NEI” 2:15 - 2:20 PM Houston, We Have A Problem 2:20 - 2:50 PM FDA Q&A 2:50 - 3:20 PM Second Acts – Reinventing Your Company 3:20 - 3:50 PM Afternoon Refreshment & Networking Break 3:50 - 4:00 PM Private Funding Trends Presentation 4:00 - 4:10 PM A View Of The Public Sector & Exit Trends 4:10 - 4:40 PM IPOs In Ophthalmology – The Class Of 2014 & Beyond 4:40 - 5:10 PM Industry Consolidation: The Good, The Bad And The Unknown 5:10 PM Wrap Up & Closing Comments 5:10 - 6:30 PM Cocktail Reception

AGENDA AT-A-GLANCE

AGENDA AT-A-GLANCE